Bryce Cleveland
Introduction
Bryce Cleveland is the former President and CEO of Scalpa, Inc., an Arizona company that marketed and sold medical devices and drug products intended to affect the structure and function of the human body. Cleveland, 42, of Scottsdale, Arizona, pleaded guilty on July 31, 2026, to mail fraud, introduction of an adulterated device into interstate commerce, and introduction of an unapproved new drug into interstate commerce — three charges tied to Scalpa’s selling of skincare products that had not been approved by the U.S. Food and Drug Administration (FDA).
The products at the center of the case were injectables marketed under names including the Fibroblast Pen, the Hyaluron Pen, Hyaluronic Acid, ScalpaJECT Hyaluronic Acid, and Scalpatox. By the time of the plea, Cleveland had already spent more than a year as a federal fugitive, having been indicted in July 2024 and apprehended late last year in Colombia.
Background Information
According to the indictment, Scalpa was a for-profit corporation incorporated in Arizona in 2015, and its products included the Fibroblast Pen, Hyaluron Pen, Hyaluronic Acid, and Scalpatox.
Scalpatox, per the plea announcement, was an unapproved and misbranded botulinum toxin product. The FDA has issued numerous warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox, and has noted adverse events associated with these products, including botulism symptoms. The device line raised a parallel concern: injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.
The Controversy or Incident That Led to Their Cancellation
Pleaded guilty; sentencing to come. Cleveland admitted through his plea agreement that he committed all 34 crimes charged in the indictment, agreed to a prison term of four to eight years, agreed to forfeit $800,000, and agreed to pay restitution for the entire scope of his criminal conduct; sentencing is set for April 9, 2027, before Judge Robert S. Ballou in Abingdon.
A federal grand jury sitting in the U.S. District Court in Abingdon returned the indictment in July 2024, charging Cleveland with 12 counts of mail fraud, nine counts of wire fraud, 12 counts of introduction of adulterated devices into interstate commerce, and one count of introduction of an unapproved new drug into interstate commerce — 34 counts in all. The indictment alleged that between 2018 and December 2020, Cleveland devised a scheme to unlawfully enrich himself by marketing, and causing others to market, unapproved devices including the Fibroblast Pen and Hyaluron Pen while representing that the devices were not regulated. It further alleged that he concealed and omitted, and caused others to conceal and omit, the fact that those pens were in fact regulated products, and that he introduced into commerce an unapproved new drug, Scalpatox.
Cleveland did not answer those charges in a courtroom for more than a year. He was apprehended in Colombia and arrested in Florida on an outstanding federal warrant by the United States Marshals Service, then made his initial appearance in the Western District of Virginia on December 9, 2025. At that stage, the U.S. Attorney’s Office stressed that an indictment is merely an allegation, and that the defendant is presumed innocent until proven guilty beyond a reasonable doubt in a court of law.
The posture changed on July 31, 2026, when Cleveland pleaded guilty to mail fraud, introduction of an adulterated device into interstate commerce, and introduction of an unapproved new drug into interstate commerce. Under the agreement, he admitted he committed all 34 crimes charged in the indictment, agreed to be sentenced to a term of imprisonment between four and eight years, agreed to pay restitution for the entire scope of his criminal conduct, and agreed to forfeit $800,000. The plea release restated the admitted scheme: between 2018 and December 2020, Cleveland marketed and delivered, and caused others to market and deliver, unapproved devices including ScalpaJECT Hyaluronic Acid and the Hyaluron Pen while making false representations that the devices were not subject to FDA regulation, and introduced and delivered the unapproved drug “Scalpatox” into commerce.
First Assistant United States Attorney Robert N. Tracci — Acting United States Attorney at the December 2025 indictment announcement — also announced the plea, which is prosecuted by Assistant U.S. Attorneys Corey Hall and Randy Ramseyer and Trial Attorney Taylor Broadbent, with Trial Attorney Justus Hogge having prosecuted at the indictment stage.
Public Reaction and Consequences
The investigation paired the FDA’s Office of Criminal Investigations with the United States Postal Inspection Service, and the fugitive phase drew in the Marshals Service and the Justice Department’s Offices of International Affairs and the Judicial Attaché in Bogotá. The December 2025 announcement was made by Tracci, FDA Special Agent in Charge Ronald Dawkins, and Postal Inspection Service Washington Division Inspector in Charge Damon E. Wood.
The case also fed a wider regulatory picture. Federal releases highlighted the FDA’s warning-letter campaign against websites illegally marketing unapproved botulinum toxin products and the adverse events, including botulism symptoms, associated with them, and explained that injectables carry heightened risk because they bypass some of the body’s key defenses against toxins and microorganisms. The Justice Department has also established a website to notify potential victims of the crimes charged, and its November 2026 sentencing release directs anyone who believes they are a victim to that notification site.
Current Status
Cleveland, described in the November 2026 release as the former President and CEO of Scalpa, is awaiting sentencing. The hearing is set for April 9, 2027, at 11:00 a.m. before Judge Robert S. Ballou in U.S. District Court in Abingdon. The plea agreement already fixes the framework: a sentence between four and eight years, an $800,000 forfeiture, and restitution covering the entire scope of his criminal conduct.
The conduct he admitted spans 2018 through December 2020, when he delivered unapproved devices including ScalpaJECT Hyaluronic Acid and the Hyaluron Pen to customers under false representations that they were not subject to FDA regulation, and introduced the unapproved drug “Scalpatox” into commerce.
Impact on Their Career/Life
The plea turns the CEO of a skincare-device brand into an admitted 34-count federal felon. The sentence to come — four to eight years, to be formalized at the April 2027 hearing — together with the $800,000 forfeiture and full restitution caps a case that began with an indictment returned in July 2024 while he was outside the United States, followed by his apprehension in Colombia and arrest in Florida. Scalpa is now described in releases only as the company he once led, its pens, hyaluronic acid injectables, and unapproved botulinum toxin product the subject of a federal fraud and public-health prosecution that has already produced a victim-notification process.
Sources
- U.S. Attorney’s Office, Western District of Virginia, “CEO of Scalpa, Inc. Pleads Guilty to FDCA Charges and Mail Fraud,” July 31, 2026 — source
- U.S. Attorney’s Office, Western District of Virginia, “CEO of Scalpa, Inc. Indicted on Mail, Wire Fraud Charges,” December 10, 2025 — source
- U.S. Attorney’s Office, Western District of Virginia, “Sentencing Scheduled in Scalpa CEO’s Criminal Case,” November 18, 2026 — source